World Journal of Advanced Research and Reviews
eISSN: 2581-9615 CODEN (USA): WJARAI
Cross Ref DOI: 10.30574/wjarr
Journal homepage: https://wjarr.com/

(REVIEW ARTICLE)

Check for updates

Advances in breast cancer treatment and management

Anil Prakash Buktare *, Abhishek Uddhavrao Shinde, Pradnya Bharat Kasar, Jayashri Khemnar and Anil Jadhav

Mahavir Institute of Pharmacy, Nashik, India.

World Journal of Advanced Research and Reviews, 2025, 26(01), 543-550

Publication history: Received on 19 February 2025; revised on 29 March 2025; accepted on 31 March 2025

Article DOI: https://doi.org/10.30574/wjarr.2025.26.1.0941

Abstract

Background: Breast cancer is one of the leading causes of cancer-related mortality worldwide. Over the years, significant advancements have been made in its detection, treatment, and management, leading to improved patient survival rates and quality of life.

Objective: This review explores recent innovations in breast cancer detection and treatment, focusing on emerging technologies, novel therapeutic approaches, and personalized medicine.

Methods: A comprehensive analysis of recent studies, clinical trials, and technological advancements in breast cancer research was conducted. Key areas of focus include advancements in imaging techniques, minimally invasive surgical procedures, radiotherapy innovations, targeted drug delivery, immunotherapy, and the role of artificial intelligence in personalized treatment strategies.

Keywords: Immunotherapy; Positron Emission Tomography; Breast Cancer; Adoptive Cell Immunotherapies

1. Introduction

Breast cancer remains one of the most prevalent malignancies worldwide, with significant impacts on patient survival and quality of life. Over the past decade, advancements in early detection, surgical techniques, radiotherapy, chemotherapy, immunotherapy, and precision medicine have revolutionized breast cancer management. These innovations have led to improved diagnostic accuracy, minimally invasive treatments, and personalized therapeutic approaches, ultimately enhancing patient outcomes.

Early detection techniques have evolved beyond traditional mammography, incorporating artificial intelligence (AI), liquid biopsy, and advanced imaging modalities such as MRI and PET-CT. Surgical innovations, including oncoplastic surgery, intraoperative imaging, and robot-assisted techniques, aim to improve tumor resection while preserving breast aesthetics. Radiotherapy has also seen major progress with hypofractionation, stereotactic radiosurgery, and proton therapy, offering more precise and effective treatment options.

In addition to conventional chemotherapy, novel drug delivery systems such as nanocarriers and micro-carriers are being explored to enhance drug efficacy and minimize toxicity. Immunotherapy has emerged as a promising treatment modality, leveraging checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines to stimulate the body's immune response against tumor cells. Furthermore, personalized medicine, driven by genomic profiling and machine learning algorithms, enables tailored treatment strategies based on individual tumor biology.

* Corresponding author: Anil Prakash Buktare

Despite these advancements, challenges such as treatment resistance, the need for more inclusive clinical trials, and the lack of standardized therapies for aggressive subtypes like triple-negative breast cancer (TNBC) remain. This review explores recent innovations in breast cancer detection, treatment, and management while highlighting future directions and ongoing challenges in the field.

2. Advances in Early Detection

AI and machine learning technologies are being integrated into breast cancer detection to enhance accuracy. AI can assist radiologists by analyzing imaging data and identifying early signs of cancer more precisely than traditional methods. (1) Liquid biopsy analyzes body fluids, such as blood, sweat, urine, tears, and breath, to find cancer biomarkers. This non-invasive method has shown promise in detecting breast cancer early. Tumor-derived DNA fragments found in the blood are emerging as promising biomarkers for early detection. Higher levels of ctDNA have been associated with advanced and early-stage breast cancer. (2)

Here are some advances:

- Ultrasound is Non-invasive and quick, but low sensitivity and resolution.
- Mammography is Standard screening with high specificity, but less effective for dense breasts and involves ionizing radiation.
- MRI: High sensitivity and detailed imaging, but expensive and lengthy. (3}
- Positron Emission Tomography (PET) and PET-CT:
- Combines metabolic and anatomical information for detailed imaging.
- Useful for diagnosing and staging cancer, as well as evaluating treatment effectiveness.
- integrating new technologies like MRI, DCE-MRI, and PET-CT to enhance early diagnosis and treatment planning.(4)

2.1. Surgical innovation in breast cancer

significant progress in the surgical management of early breast carcinoma, focusing on innovations that minimize toxicity, improve cosmesis, and enhance patient quality of life. Techniques such as hypofractionation, APBI, IMRT, and IORT represent important steps forward in breast conservation therapy. (5)

- Neoadjuvant Chemotherapy (NACT) and Breast-Conserving Surgery (BCS)
- Hypofractionated Radiotherapy and 3D Conformal Radiotherapy (3DCRT)
- Intraoperative Imaging and Robot-Assisted Surgery

Oncoplastic Surgery (6)

Ultrasound Elastography:

- Uses ultrasound waves to assess the stiffness or elasticity of breast tissue, helping differentiate between benign and malignant lesions.

Newer Ultrasound Localization Techniques:

- Techniques like Magseed®, RFID localization, Savi Scout®, and Pintuition® assist in precisely excising tissue, improving cosmetic outcomes and reducing re-excision rates. (7)

2.2. Radiotherapy Advances

Stereotactic Radiosurgery (SRS): This is a non-surgical radiation therapy used to treat functional abnormalities and small tumors of the brain. It delivers precisely-targeted radiation in fewer high-dose treatments than traditional therapy (8)

Hypofractionation is a radiation therapy technique where patients receive higher doses of radiation over fewer treatment sessions compared to conventional fractionation.

Hypofractionated schedules and accelerated partial breast irradiation (APBI) have shown non-inferiority to conventional fractionation in terms of tumor control and treatment toxicity. (9)

- Image-Guided Radiation Therapy (IGRT)
- Volumetric Modulated Arc Therapy (VMAT)
- Deep Inspiration Breath Hold (DIBH)
- Proton Therapy and Carbon-Ion Therapy
- MR-Guided Radiotherapy (MRgRT) (10)

These technological advancements have led to more personalized, precise, and effective treatment approaches for breast cancer, significantly improving patient outcomes and quality of life.

3. Immunotherapy approaches

Checkpoint inhibitors, like the anti-PD-L1 antibody atezolizumab, are designed to block immune checkpoints that typically inhibit immune responses. This allows the privileged to better recognize and attack cancer cells. Atezolizumab, when combined with chemotherapy, has been approved for treating metastatic triple-negative breast cancer. Despite their benefits, checkpoint inhibitors often show modest response rates and can cause immune-mediated side effects like pneumonitis and colitis. (11)

3.1. Targeting Tumor Microenvironment in Breast Cancer

Local Tumor Hyperthermia: Enhances immune responses by raising tumor tissue temperature, increasing immune cell activation and sensitivity to immune attacks. Radiation Therapy: Improves antigen presentation and reduces immune suppressors within the cellular ecosystem of a tumor, making tumors more responsive to immunotherapy. (12)

3.2. Adoptive Cell Immunotherapies

CAR T Cell Therapy: Genetic modification of T cells to target cancer-specific antigens like MUC1, showing target-specific cytotoxicity and tumor growth reduction. Challenges include selecting optimal antigens and managing side effects. Tumor-Infiltrating Lymphocyte (TIL) Therapy: Isolating and expanding tumor-infiltrating lymphocytes for reinfusion, enhancing the immune response. Personalized approach with complex processing requirements and side effects management. (13)

3.3. Cancer Vaccines

Peptide-Based Vaccines: Use short protein fragments to stimulate immune responses, with easy manufacturing and favorable toxicity profiles.

DNA-Based Vaccines: Deliver genetic material to induce robust immune responses, involving both humoral and cellular immunity, but require suitable delivery vectors.

Dendritic Cell (DC) Vaccines: Load dendritic cells with tumor antigens to stimulate strong immune responses, capable of activating both T-cells and antibodies. These vaccines aim to enhance the immune system's capacity to identify and attack breast cancer cells. (14)

3.4. Combination Therapy Proposal for Breast Cancer

A proposed combination therapy involves co-activating immune cells (macrophages, NK cells, cytotoxic T cells) using specific cytokines (IL-2, TNF-α, IFN-γ). Extracorporeal immune response reactivation involves isolating and stimulating patient immune cells with tumor antigens and cytokines before reinfusing them. Encapsulated tumor pieces with Th1 cytokines and chemokines are reintroduced to stimulate a localized immune response.

This approach aims to enhance the body's immune response to target and eliminate cancer cells. (15)

4. Chemotherapy innovations

4.1. Nanocarriers in Breast Cancer Chemotherapy

Advantages: Enhance drug delivery, increase circulation time, and selectively target tumors to reduce systemic exposure and adverse effects.

Mechanisms: Utilize passive targeting (EPR effect) and active targeting (ligands like antibodies) to improve tumor localization.

These innovations aim to improve breast cancer treatment by enhancing drug delivery, reducing toxicity, and increasing efficacy. (16)

4.2. Active and Passive Targeting

Passive targeting exploits the Enhanced Permeability and Retention (EPR) effect to localize drugs at the site of tumorigenesis. Active targeting involves attaching ligands like antibodies or peptides to nanocarriers to specifically target tumor cells. (17)

4.3. Micro-Carriers in Chemotherapy

Micro-carriers are targeted nanoscale therapeutic vehicles designed to administer highly liposoluble drugs. They help overcome solubility issues, providing controlled and sustained drug release. This reduces the need for toxic solvents and minimizes side effects. Micro-carriers can improve the solubility and stability of chemotherapeutic agents, ensuring consistent therapeutic levels in the bloodstream.these systems facilitate localized delivery, amplifying within the tumor microenvironment and minimizing off-target effects on healthy cells. This precision-focused strategy amplifies therapeutic efficacy against cancer while mitigating harm to healthy tissues, improving treatment outcomes and patient tolerability. (18)

4.4. Neoadjuvant Chemotherapy (NAC)

Neoadjuvant chemotherapy (NAC) is administered before the main surgical treatment. The strategy prioritizes tumor reduction to improve operability, enabling safer and more effective surgical intervention. This approach can also convert Enable surgical resection for tumors originally classified as inoperable. Additionally, NAC can help assess the tumor's response to chemotherapy, providing valuable information for further treatment planning. It can also eliminate Minute cancerous foci that could have spread beyond the primary tumor site, potentially reducing the risk of recurrence.

NAC has become an increasingly common approach in treating breast cancer, aiming to improve surgical outcomes and prognosis by enabling more conservative surgeries and improving overall survival rates. (19)

5. Personalized Medicine and precision

5.1. Personalized Medicine

Personalized medicine involves the use of genetic and molecular information to determine the best treatment options for patients. Recent studies have identified genes and molecules that can predict drug response and symptom severity.

Genetic Testing and Biomarkers: Genetic profiling can identify specific mutations and biomarkers in breast cancer tumors. For example, mutations in the BRCA1 and BRCA2 genes can significantly influence treatment decisions. Identifying these mutations allows for targeted therapies that are more likely to be effective. (20)

Support Vector Machine (SVM) is a supervised machine learning algorithm that classifies high-dimensional data by drawing a decision boundary called a hyperplane. It's effective for disease stratification in breast cancer by accurately classifying subtypes using diverse data types like transcriptomics, proteomics, and radiomics. SVM models handle large datasets efficiently, providing valuable insights for personalized treatment plans and improving detection and therapeutic efficacy in breast cancer patients. They offer high accuracy and versatility, making them a revolutionary platform for personalized medicine. (21)

several aspects of precision medicine within the framework of metastatic breast cancer (MBC).

- Driver Mutations: Identifying and targeting specific driver mutations like ER, HER2, PIK3CA, and AKT1 to develop effective treatments.
- Circulating Tumor DNA (ctDNA): Using ctDNA for early detection of resistance mutations and to monitor treatment response.
- Genomic Tools: Developing bioinformatic tools to identify driver mutations and assess pathway activation.

- Combination Therapies: Utilizing combination therapies to address tumor heterogeneity and overcome resistance.
- Personalized Medicine Trials: Implementing precision medicine guided by tumor-specific genetic mutations to enhance therapeutic efficacy and survival rates. (22)

Genomic Profiling: Using next-generation sequencing (NGS) and genomic profiling to identify genetic mutations and tailor treatments accordingly.

Molecular Subtyping: Molecular subtyping of triple-negative breast cancer (TNBC) to design precision medicine-based clinical trials. (23)

5.2. Targeted Therapies in Breast Cancer

Targeted therapies in breast cancer involve drugs designed to precisely identify and attack cancer cells based on specific genetic alterations. Examples include PARP inhibitors, immune checkpoint inhibitors, and antibody-drug conjugates. These therapies work by interfering with molecules and signaling pathways critical for cancer cell survival, offering a more effective and less toxic alternative to traditional chemotherapy. They are a cornerstone of personalized medicine, tailored to individual genetic profiles to improve patient outcomes and manage resistance. (24)

6. Future Directions

6.1. Role of Gut Microbiota

One exciting future direction in the realm of nutritional metabolomics and breast cancer research is the investigation of the role of gut microbiota. The gut microbiota consists of trillions of microorganisms, including bacteria, fungi, viruses, and archaea, which inhabit the digestive tract. These microorganisms play a key role in driving change in the metabolism of dietary components and can influence breast cancer risk. (25)

6.2. Combining PI3K Inhibitors with Other Therapies

Current studies seek to determine the best combination of PI3K inhibitors with endocrine therapy, chemotherapy, CDK 4/6 inhibitors, immune checkpoint inhibitors, and other novel targeted agents to enhance treatment efficacy and overcome resistance. (26)

6.3. Interpretable Deep Architectures

Creating deep learning models that are interpretable and can handle complex radiological images. This includes using text features to express radiomic features and designing models that pay attention to attributes within breast cancer images. (27)

6.4. Hybrid and Portable Systems

Creating hybrid MWI systems combined with other imaging modalities, like sonography, and developing portable MWI devices for convenient and accessible breast cancer screening. (28)

6.5. Radiomics and Genomics

Integrating advanced image analysis (radiomics) with genomic, transcriptomic, and proteomic data to personalize diagnosis and treatment.

6.6. Machine Learning and AI

Leveraging advanced machine learning and artificial intelligence techniques to analyze and interpret the massive volumes of information generated from radiogenomic studies. (29)

6.7. Challenges

Resistance to Treatment: Many patients shown no reaction to biological therapy, or they relapse after an initial response. This is due to complex, intrinsic or extrinsic Mechanisms of resistance, such as reduced antigen expression and changes in gene expression pathways. (30)

Ethnic Diversity: Many studies that have examined TMB have predominantly included patients of European descent. This limited scope raises concerns about the applicability of TMB as a biomarker across different ethnic groups. Genetic variations and differences in cancer biology among ethnicities can impact how tumors respond to treatment, and therefore, more inclusive studies are essential. (31)

- Lack of Standardized Treatment for Triple-Negative Breast Cancer (TNBC)
- Current treatments rely on chemotherapy, which has limited long-term effectiveness.
- New treatments like immunotherapy and antibody-drug conjugates are being explored but are not yet standardized. (32)

7. Conclusion

Breast cancer management has witnessed remarkable progress in recent years, with innovations in early detection, surgical techniques, radiotherapy, systemic therapies, and personalized medicine significantly improving patient outcomes. Advances such as AI-assisted diagnostics, liquid biopsies, targeted therapies, and immunotherapy have enhanced the precision and effectiveness of treatment while minimizing side effects. However, challenges such as therapy resistance, treatment costs, and accessibility disparities continue to pose significant hurdles in achieving optimal patient care worldwide. Future research should focus on overcoming these challenges through the development of more effective, affordable, and personalized treatment strategies. Collaborative efforts between researchers, clinicians, and policymakers will be crucial in ensuring that these advancements reach all patients, ultimately reducing breast cancer-related morbidity and mortality on a global scale.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Abdul Halim, A. A., Andrew, A. M., Mohd Yasin, M. N., Abd Rahman, M. A., Jusoh, M., Veeraperumal, V., Rahim, H. A., Illahi, U., Abdul Karim, M. K., & Scavino, E. (2021). Existing and emerging breast cancer detection technologies and its challenges: A review. Applied Sciences, 11(22), 10753. https://doi.org/10.3390/app112210753.

[2] Li, J., Guan, X., Fan, Z., Ching, L.-M., Li, Y., Wang, X., Cao, W.-M., & Liu, D.-X. (2020). Non-invasive biomarkers for early detection of breast cancer. Cancers, 12(10), 2767. https://doi.org/10.3390/cancers12102767.

[3] Milosevic, M., Jankovic, D., Milenkovic, A., & Stojanov, D. (2018). Early diagnosis and detection of breast cancer. Technology and Health Care, 26(6), 1–31. https://doi.org/10.3233/THC-181277.

[4] Bhushan, A., Gonsalves, A., & Menon, J. U. (2021). Current state of breast cancer diagnosis, treatment, and theranostics. Pharmaceutics, 13(5), 723. https://doi.org/10.3390/pharmaceutics13050723.

[5] Keisch, M., & Vicini, F. (2005). Applying innovations in surgical and radiation oncology to breast conservation therapy. The Breast Journal, 11(Suppl. 1), S24–S29. https://doi.org/10.1111/j.1075-122X.2005.181277.

[6] Mahmood, A. S., Fakhir, O. J., Shakir, M. A., Al-Taie, R. H., & Ismail, M. (2024). Innovations in breast cancer surgery and their adoption and adaptation in Iraq. Cureus, 16(8), e66506. https://doi.org/10.7759/cureus.66506.

[7] Chopra, S., Khosla, M., & Vidya, R. (2023). Innovations and challenges in breast cancer care: A review. Medicina, 59(5), 957. https://doi.org/10.3390/medicina59050957.

[8] Riaz, N., Jeen, T., Whelan, T. J., & Nielsen, T. O. (2023). Recent advances in optimizing radiation therapy decisions in early invasive breast cancer. Cancers, 15(4), 1260. https://doi.org/10.3390/cancers15041260.

[9] Kron, T., & Chua, B. (2014). Radiotherapy for breast cancer: How can it benefit from advancing technology? European Medical Journal Oncology, 2, 83-90.

[10] Demircan, N. V., & Bese, N. (2024). New approaches in breast cancer radiotherapy. European Journal of Breast Health, 20(1), 1-7. https://doi.org/10.4274/ejbh.galenos.2023.2023-11-4.

[11] García-Aranda, M., & Redondo, M. (2019). Immunotherapy: A challenge of breast cancer treatment. Cancers, 11(12), 1822. https://doi.org/10.3390/cancers11121822.

[12] Retecki, K., Seweryn, M., Graczyk-Jarzynka, A., & Bajor, M. (2021). The immune landscape of breast cancer: Strategies for overcoming immunotherapy resistance. Cancers, 13(23), 6012. https://doi.org/10.3390/cancers13236012.

[13] Sun, X., Liu, K., Lu, S., He, W., & Du, Z. (2022). Targeted therapy and immunotherapy for heterogeneous breast cancer. Cancers, 14(21), 5456. https://doi.org/10.3390/cancers14215456.

[14] Marmé, F. (2016). Immunotherapy in breast cancer. Oncology Research and Treatment, 39(6), 335–345. https://doi.org/10.1159/000446340.

[15] Galván Morales, M. A., Barrera Rodríguez, R., Santiago Cruz, J. R., & Teran, L. M. (2020). Overview of new treatments with immunotherapy for breast cancer and a proposal of a combination therapy. Molecules, 25(23), 5686. https://doi.org/10.3390/molecules25235686.

[16] Fraguas-Sánchez, A. I., & Torres-Suárez, A. I. (2020). Development of innovative formulations for breast cancer chemotherapy. Cancers, 12(11), 3281. https://doi.org/10.3390/cancers12113281.

[17] Franco, A., Di Leone, A., Conti, M., Fabi, A., Carbognin, L., Terribile, A. D., Belli, P., Orlandi, A., Sanchez, M. A., Moschella, F., et al. (2023). An innovative scoring system to select the optimal surgery in breast cancer after neoadjuvant chemotherapy. Journal of Personalized Medicine, 13(8), 1280. https://doi.org/10.3390/jpm13081280.

[18] Taghavi, B. A., Alizadeh, N., Saeedi, H., Ahangar, N. K., Derakhshani, A., Hajiasgharzadeh, K., Silvestris, N., Baradaran, B., & Brunetti, O. (2022). Targeted therapy of B7 family checkpoints as an innovative approach to overcome cancer therapy resistance: A review from chemotherapy to immunotherapy. Molecules, 27(11), 3545. https://doi.org/10.3390/molecules27113545.

[19] Chiappa, C., Greta, M., Leoni, M., Ietto, G., Inversini, D., Ballabio, A., Bonetti, A., Mangano, A., Gueli, R., Carcano, G., & Rovera, F. A. (2024). Neoadjuvant chemotherapy in breast cancer: Evaluation of the impact on surgical outcomes and prognosis. Cancers, 16(13), 2332. https://doi.org/10.3390/cancers16132332.

[20] Chan, C. W. H., Law, B. M. H., So, W. K. W., Chow, K. M., & Waye, M. M. Y. (2017). Novel strategies on personalized medicine for breast cancer treatment: An update. International Journal of Molecular Sciences, 18(11), 2423. https://doi.org/10.3390/ijms18112423.

[21] Ozer, M. E., Sarica, P. O., & Arga, K. Y. (2020). New machine learning applications to accelerate personalized medicine in breast cancer: Rise of the support vector machines. OMICS: A Journal of Integrative Biology, 24(5), 241–252. https://doi.org/10.1089/omi.2020.0001.

[22] Arnedos, M., Vicier, C., Loi, S., Lefebvre, C., Michiels, S., Bonnefoi, H., & Andre, F. (2015). Precision medicine for metastatic breast cancer—limitations and solutions. Nature Reviews Clinical Oncology, 12(10), 693–704. https://doi.org/10.1038/nrclinonc.2015.123.

[23] Hossain, F., Majumder, S., David, J., & Miele, L. (2021). Precision medicine and triple-negative breast cancer: Current landscape and future directions. Cancers, 13(15), 3739. https://doi.org/10.3390/cancers13153739.

[24] Afzal, M. Z., & Vahdat, L. T. (2024). Evolving management of breast cancer in the era of predictive biomarkers and precision medicine. Journal of Personalized Medicine, 14(7), 719. https://doi.org/10.3390/jpm14070719.

[25] Vahid, F., Hajizadeghan, K., & Khodabakhshi, A. (2023). Nutritional metabolomics in diet–breast cancer relations: Current research, challenges, and future directions—A review. Biomedicines, 11(7), 1845. https://doi.org/10.3390/biomedicines11071845.

[26] Fuso, P., Muratore, M., D'Angelo, T., Paris, I., Carbognin, L., Tiberi, G., Pavese, F., Duranti, S., Orlandi, A., Tortora, G., & Scambia, G. (2022). PI3K inhibitors in advanced breast cancer: The past, the present, new challenges and future perspectives. Cancers, 14(9), 2161. https://doi.org/10.3390/cancers14092161.

[27] Nasser, M., & Yusof, U. K. (2023). Deep learning-based methods for breast cancer diagnosis: A systematic review and future direction. Diagnostics, 13(1), 161. https://doi.org/10.3390/diagnostics13010161.

[28] AlSawaftah, N., El-Abed, S., Dhou, S., & Zakaria, A. (2022). Microwave imaging for early breast cancer detection: Current state, challenges, and future directions. Journal of Imaging, 8(5), 123. https://doi.org/10.3390/jimaging8050123.

[29] Gallivanone, F., Bertoli, G., & Porro, D. (2022). Radiogenomics, breast cancer diagnosis and characterization: Current status and future directions. Methods and Protocols, 5(5), 78. https://doi.org/10.3390/mps5050078.

[30] Henriques, B., Mendes, F., & Martins, D. (2021). Immunotherapy in breast cancer: When, how, and what challenges? Biomedicines, 9(11), 1687. https://doi.org/10.3390/biomedicines9111687.

[31] Barroso-Sousa, R., Pacífico, J. P., Sammons, S., & Tolaney, S. M. (2023). Tumor mutational burden in breast cancer: Current evidence, challenges, and opportunities. Cancers, 15(15), 3997. https://doi.org/10.3390/cancers15153997.

[32] Burguin, A., Diorio, C., & Durocher, F. (2021). Breast cancer treatments: Updates and new challenges. Journal of Personalized Medicine, 11(8), 808. https://doi.org/10.3390/jpm11080808.